• The council will serve as an advisory group, guiding BVI on market insights, clinical practice and surgical education across Europe.
• The initiative builds on the momentum of BVI’s US Surgical Leadership Council, extending its collaborative model to key European markets.

WALTHAM, Mass., May 6th, 2026 — BVI, a global ophthalmic device company, today announced the formation of its European Surgical Leadership Council. The group includes seven surgeons, key figures in their respective fields, representing anterior segment, glaucoma and vitreoretinal specialties across key European markets.

The European council expands BVI’s efforts to work closely with surgeons to better understand regional clinical practices, evolving market needs and opportunities to support surgical performance and patient care.

The initiative builds on the foundation established by the company’s US Surgical Leadership Council and reflects its ongoing focus on strengthening global clinical partnerships.

“We are pleased to collaborate with BVI as part of its European Surgical Leadership Council. Initiatives like this create opportunities to exchange insights, share best practices and contribute to the advancement of ophthalmic care across different health care systems,” said Sheraz Daya, a member of BVI’s European Surgical Leadership Council.

The inaugural European council members include:

• Sheraz Daya, MD, United Kingdom
• Daniel Elies, MD, Spain
• Damien Gatinel, MD, France
• Fernando Llovet, MD, Spain
• Radhika Rampat, MD, United Kingdom
• Gok Ratnarajan, MD, United Kingdom
• Tommaso Rossi, MD, Italy

„The European Surgical Leadership Council provides a platform for BVI to engage directly with surgeons across the region, a key market for the company. Through these collaborations, we aim to foster the exchange of insights, support ongoing innovation, and gather feedback that informs our approach to clinical education, product development, and market strategy,” said Andy Chang, Chief Commercial Officer at BVI.

The council will support BVI across three areas: strategic market insights, advocacy and education, and clinical and surgical guidance, underscoring the company’s commitment to partnering with surgeons to inform its approach to clinical practice, education and the development of surgical solutions.

About BVI

BVI® is a leading innovator in eye health, with a long-standing legacy of shaping ophthalmic care through advanced technology. Building on nearly nine decades of expertise, from foundational surgical instruments to premium intraocular lenses and next-generation platforms, BVI partners closely with surgeons to deliver technology designed to support surgical performance and patient care. Serving surgical teams in more than 90 countries, BVI is committed to improving vision for patients worldwide.

To learn more about BVI and its mission to advance the future of vision, visit https://www.bvimedical.com

***

• CE Mark under the European Union Medical Device Regulation (EU MDR) achieved for Virtuoso®, BVI’s first dual-function phaco-vitrectomy platform designed to deliver advanced control, efficiency, and versatility for both cataract and vitreoretinal surgery.
• First patient successfully treated at LMU Klinikum in Munich, Germany, in December 2025. This milestone builds on Virtuoso®’s presence across key 2025 industry forums, including EURETINA, ESCRS, and FloRETINA, and continued into 2026 at the Munich Retina Meeting, where the platform was featured in its first live surgery, reinforcing its design focus on fluidics stability, workflow efficiency, and the real-world demands of ophthalmic surgery.

WALTHAM, Mass., April 20th, 2026 — BVI, a global leader in ophthalmic device innovation, today announced that Virtuoso® has received the CE Mark under the European Union Medical Device Regulation (EU MDR), enabling commercialization across markets recognizing the CE Mark. Virtuoso® is BVI’s next-generation phaco-vitrectomy surgical platform, a dual-function system designed to support both cataract and vitreoretinal procedures on a single, integrated platform.

Virtuoso® is engineered to introduce a new level of control through novel fluidics, consistent energy delivery, advanced vitreous cutting and aspiration performance, and a seamless Operating Room (OR) workflow. CE Mark certification under MDR represents a major milestone in BVI’s continued expansion in the premium surgical equipment segment and its broader mission to support surgeons with flexible, future-ready solutions.

“Virtuoso® represents a significant advance in surgical equipment design, bringing together precision, intuitive ease of use that supports OR efficiency, and world-class versatility for both the front and the back of the eye,” said Jim Hollingshead, President and CEO of BVI. “With CE Mark certification under the European Medical Device Regulation, we are making this leading-edge platform available to surgeons across Europe, designed to elevate surgical control, efficiency, and outcomes, reflecting BVI’s continued commitment to meaningful innovation in eye health.”

One Platform Designed for Multi-Specialty Excellence

Virtuoso® is purpose-built to support anterior, posterior, and combined procedures, addressing the evolving needs of multi-specialty centers, ambulatory surgical centers, and high-efficiency operating environments. Key innovations include:

• Equality™ Fluidics Control. A proprietary intraocular pressure (IOP) management system designed to actively maintain a consistent target IOP throughout all procedural steps.
• Resolute™ Ultrasound Delivery. An intelligent energy optimization system designed to deliver target energy regardless of lens hardness.
• Velvet™ Vitrectomy Probe. A high-speed, dual-pneumatic, dual-blade vitrectomy drive designed for controlled and efficient posterior and anterior vitrectomy.
• EvenFlow™ Automatic FAX. An automated fluid-air exchange solution providing machine-controlled IOP control during surgical media exchanges.
• inVITe™ Valved Entry System. A flexible entry system with a high-flow directional infusion cannula designed to improve surgical efficiency and maintain stable intraoperative fluidics.
• EasyFit™ All At Once Setup. A streamlined operating room setup designed to reduce turnover time and improve procedural consistency.

Clinical Validation

As part of BVI’s commitment to clinical collaboration and evidence generation, Virtuoso® is currently being evaluated in a pre-market, prospective, single-center, single-arm clinical investigation at LMU Klinikum, Munich, Germany, led by Professor Siegfried Priglinger. The first patient procedure was successfully performed in December 2025, marking an important clinical milestone for the platform.

“During this first phase of our clinical evaluation, Virtuoso® has demonstrated a thoughtful integration of fluidics stability, responsiveness, and workflow efficiency, designed with the realities of combined cataract and vitreoretinal surgery in mind, and we look forward to further evaluating its performance as the study progresses,” said Prof. Siegfried Priglinger, MD, Chair of the Department of Ophthalmology at LMU Klinikum.

The 2025 EURETINA, ESCRS, and FloRETINA congresses featured the first-ever Virtuoso® abstracts in their scientific programs, presenting data on post-occlusion break surge that demonstrated the system’s responsiveness in recovering IOP stability. Additional findings highlighted energy delivery consistency, supporting the ability to maintain target energy and enabling lower energy setpoints, alongside enhanced aspiration efficiency versus leading platforms in both BSS and vitreous, and higher cutter stiffness without compromising efficiency at high degrees of bending. This scientific foundation was further extended into 2026 at the Munich Retina Meeting, where Virtuoso® was featured in its first live surgery, demonstrating performance in a real-world surgical setting.

Virtuoso® is positioned to compete at the highest tier of ophthalmic surgical systems, supporting providers seeking flexible, scalable, and cost-effective platforms. The system further strengthens BVI’s value proposition through seamless integration with its expanding portfolio of consumables and intraocular lenses. Commercial availability is expected to begin across Europe in Q3 2026, with expansion into additional international markets planned thereafter.

About BVI

BVI® is a leading innovator in eye health, with a long-standing legacy of shaping ophthalmic care through advanced technology. Building on nearly nine decades of expertise, from foundational surgical instruments to premium intraocular lenses and next-generation platforms, BVI partners closely with surgeons to deliver technology designed to support surgical performance and patient care. Serving surgical teams in more than 90 countries, BVI is committed to improving vision for patients worldwide.

To learn more about BVI and its mission to advance the future of vision, visit https://www.bvimedical.com

Press Contact
David Chavez
Global Communications Lead
[email protected]
+1 (857) 869 8706

Waltham (Massachusetts, USA), 19. Januar 2026. BVI, ein weltweit führendes Unternehmen auf dem Markt für ophthalmologische Geräte, hat heute die Ernennung von Jim Hollingshead zum Präsident und Chief Executive Officer bekanntgegeben. Hollingshead tritt die Nachfolge von Shervin Korangy an, der weiterhin als Berater für BVI tätig sein wird und eine neue Aufgabe als Senior Advisor bei TPG Capital übernimmt.

Hollingshead verfügt über mehr als 20 Jahre Erfahrung in der Führung von Unternehmen aus den Bereichen Medizintechnik und Life Sciences, denen er erfolgreich zu Wachstum verholfen hat. Zuletzt war er als CEO von Insulet tätig, einem innovativen Marktführer im Bereich der Insulinverabreichung. Während Hollingsheads Amtszeit baute Insulet seine Marktführerschaft durch ein erweitertes Produktangebot aus, darunter die Einführung des branchenweit ersten automatischen Insulinverabreichungssystems mit Patch-Pumpe. Zuvor war Hollingshead 12 Jahre lang bei ResMed tätig, zuletzt als Präsident für den Geschäftsbereich Schlaf- und Beatmungsmedizin.

„Schon seit langem begeistern mich technologische Innovationen, durch die Patientenerfahrungen und -ergebnisse verbessert werden“, sagte Hollingshead. „BVI liefert für die Augenversorgung vertrauenswürdige, innovative Lösungen, die auf die individuellen Bedürfnisse von Ärzten und ihren Patienten zugeschnitten sind. Es ist ein Privileg, mit dem BVI-Team zusammenarbeiten zu können, denn wir können auf der bereits starken Dynamik des Unternehmens aufbauen und mehrere neue, branchenführende Plattformen einführen.“

In den letzten Jahren hat BVI diese Dynamik beibehalten und sein zweckgebundenes Portfolio erheblich erweitert. Das Unternehmen hat eine der solidesten Produktpipelines in der Branche entwickelt und bietet nun eine vollständige Verfahrenslösung für den Markt der Katarakt- und Netzhautchirurgie an. Das Unternehmen hat aufgrund der weltweit wachsenden Nachfrage seine Plattform für Intraokularlinsen (IOL) erweitert. Darüber hinaus wurden neue Produktlinien wie SERENITY und SERENITY Toric für das Sehen im Zwischenbereich und in der Ferne eingeführt. Im Jahr 2025 erhielt BVI die Zulassung der FDA für seine trifokale IOL FINEVISION HP – hierdurch konnte das Unternehmen seine weltweit führende Position bei Premium-IOLs auch auf die USA ausweiten. Das Unternehmen stellte neben dem von der FDA zugelassenen Leos™-Glaukomsystem – ein bedeutender Fortschritt in der Glaukombehandlung – auch Virtuoso® vor, eine neuartige Phako-Vitrektomie-Plattform mit Doppelfunktion für Katarakt- und vitreoretinale Eingriffe.

„Jims passt dank seinem strategischem Weitblick, seinem Fachwissen und seiner Erfolgsbilanz im Bereich Innovation und Transformation in der Branche für Medizinprodukte hervorragend zu BVI, gerade weil das Unternehmen seine Marktführerschaft weiter ausbauen und seinen Einfluss weltweit vergrößern wird“, so Ron Labrum, Chairman von BVI. „Wir möchten Shervin für seine Führungsrolle bei der Entwicklung eines der innovativsten Produktportfolios der Branche danken, und das Team wird auch weiterhin von seinem Fachwissen profitieren.“

„Ich möchte dem gesamten BVI-Team für seine Unterstützung bei der erfolgreichen Transformation des Unternehmens in eine dynamische Plattform danken“, sagte Korangy. „Besonders stolz bin ich auf das breite Portfolio und die Pipeline, die wir aufgebaut haben, denn hiermit können wir den langjährigen Status quo in der Branche herausfordern. Ich freue mich, dass ich das Unternehmen weiterhin unterstützen kann, während es unter Jims Führung seinen Wachtumsweg weiter verfolgen wird.“

Über BVI
BVI® ist ein diversifiziertes, weltweit tätiges Unternehmen für ophthalmologische Produkte, das sich zum Ziel gesetzt hat, qualitativ hochwertige Lösungen und Innovationen für die Augenchirurgie und eine verbesserte Sehkraft der Patienten zu liefern. BVI verfügt über neun Jahrzehnte Erfahrung in der Entwicklung führender Produkte und Lösungen und arbeitet mit Augenchirurgen zusammen, damit die Sehkraft von Millionen von Patienten auf der ganzen Welt verbessert werden kann. BVI unterstützt chirurgische Teams in mehr als 90 Ländern weltweit, entweder direkt oder über ein Netzwerk von vertrauenswürdigen Händlern.

Wenn Sie mehr über BVI und darüber erfahren möchten, wie wir die Zukunft des Sehens neu ausrichten, besuchen Sie https://www.bvimedical.com

Pressekontakt
David Chavez
Global Communications Lead
[email protected]
+1 (857) 869 8706

• BVI received four awards in the 2025 Medical Device Network Excellence Awards—for Innovation, Product Launches, R&D, and Investments—recognizing its leadership in advancing ophthalmic technology and global growth.
• Key achievements include the launch of SERENITY IOLs with ISOFOCAL technology, FDA clearance of the Leos™ glaucoma system, and a $1 billion capital raise supporting strategic expansion and continued innovation.

WALTHAM, Mass., July 9th, 2025 – BVI, a leading global ophthalmic device company dedicated to sitting at the forefront of advancements in eye surgery, has been recognized with four prestigious accolades in the 2025 Medical Device Network Excellence Awards. The company earned top honors in Innovation, Research and Development, Investments, and Product Launches, underscoring its leadership in advancing eye care technology, strategic growth, and breakthrough product development.

The Excellence Awards celebrate the most impactful achievements and innovations across the medical device industry. Powered by Global Data’s proprietary business intelligence, the program highlights the companies and individuals driving meaningful changes across twelve key categories including Innovation, Product Launches, R&D, Safety, and Marketing.

“Being recognized across four distinct categories is an extraordinary honor and a reflection of the energy and purpose that drive our teams every day,” said Shervin Korangy, President & Chief Executive Officer at BVI. “These awards validate our vision to lead the ophthalmic industry not only through cutting-edge technologies, but also through bold financial strategy and meaningful global expansion. We’re excited by the impact we’re making — and even more inspired by what’s ahead.”

BVI was recognized in the following categories:

• Breakthrough Innovation in Ophthalmic Implants: For its patented ISOFOCAL technology, featured in the newly launched SERENITY and SERENITY Toric premium monofocal IOLs.
• Award-Winning Product Launch: SERENITY IOL Portfolio: For introducing the SERENITY IOL series, representing the second generation of BVI’s ISOPURE family.
• R&D Leadership in Minimally Invasive Glaucoma Technology: For the Leos™ Laser Endoscopy Ophthalmic System, a groundbreaking platform that combines laser treatment with endoscopic visualization. Leos has received FDA 510(k) clearance and is planned for commercial launch in late 2025.
• Strategic Capital Investment and Global Expansion: Following the successful $1 billion capital raise in partnership with TPG, enabling manufacturing expansion, global footprint growth, and accelerated product innovation.

“Winning in both the Innovation and Product Launch categories is a powerful acknowledgment of the incredible work our teams have done to bring the SERENITY IOL portfolio to market,” said Andrew Chang, Chief Commercial Officer at BVI. “We’re proud to set a new standard in monofocal IOLs and excited for what lies ahead. With upcoming launches on the horizon, we remain deeply committed to shaping the future of ophthalmology.”

These four awards reflect the strength of BVI’s strategy, the depth of its innovation, and the dedication of its global teams. As the company continues to expand its portfolio, invest in next-generation technologies, and scale global operations, BVI is well-positioned to shape the future of ophthalmology and deliver lasting value to patients, surgeons, and partners around the world.

About BVI

BVI® is a diversified global ophthalmic device company with a mission to deliver high-quality solutions and innovation for advancing eye surgery and improving patients’ vision. With nine decades of developing leading products and solutions, BVI partners with ophthalmic surgeons to improve the vision of millions of patients across the globe. Our organization supports surgical teams in more than 90 countries worldwide, either directly or through our network of trusted distributors.

To learn more about BVI and its mission to advance the future of vision, visit https://www.bvimedical.com

Press Contact
David Chavez
Global Communications Lead
[email protected]
+1 (857) 869 8706

• Positions company for several new product launches and scaling of operations to meet rising demand globally
• $1 billion of new capital raised to refinance debt and fund accelerated growth

Waltham, MA, March 10, 2025 – BVI Medical, a leading global ophthalmic device company dedicated to sitting at the forefront of advancements in eye surgery, today announced the completion of a $1 billion strategic capital raise in partnership with TPG, a leading global alternative asset management firm. This investment, which fully refinances BVI’s existing debt and adds new equity from both TPG and new investors, strengthens the company’s financial position as it looks to accelerate product innovation and expand its global footprint.

This financing follows a period of accelerated momentum for BVI, during which the company has significantly grown its portfolio of product offerings and built one of the most robust product pipelines in the industry. Most recently, BVI expanded its IOL manufacturing in Europe to meet growing global demand, introduced new product lines such as SERENITY and SERENITY Toric premium monofocal IOLs, and strengthened its market position through strategic acquisitions.

“This investment marks a pivotal moment for BVI as we scale our capabilities to meet the rising demand for advanced ophthalmic solutions,” said Shervin Korangy, President and CEO. “We are redefining the future of eye surgery and changing the competitive landscape by driving the launch of breakthrough technologies that will empower surgeons worldwide.”

“TPG is proud to continue our partnership with BVI as it works to scale its global impact in ophthalmic care,” said Kendall Garrison, Partner at TPG. “The company has strengthened its market position while advancing patient care worldwide and this investment will further drive innovation and expansion. We look forward to supporting BVI’s continued success,” added John Schilling, MD, Co-Managing Partner at TPG Capital.

***

About BVI Medical

BVI® is a diversified global ophthalmic device company with a mission to deliver high-quality solutions and innovation for advancing eye surgery and improving patients’ vision. With nine decades of developing leading products and solutions, BVI partners with ophthalmic surgeons to improve the vision of millions of patients across the globe. Our organization supports surgical teams in more than 90 countries worldwide, either directly or through our network of trusted distributors.

To learn more about BVI Medical and its mission to advance the future of vision, visit https://www.bvimedical.com.

Press Contact

David Chavez

Global Communications Lead

[email protected]

+1 (857) 869 8706